Cargando…

MiRNA505/NET1 Axis Acts as a CD8(+) T-TIL Regulator in Non-Small Cell Lung Cancer

INTRODUCTION: Lung adenocarcinoma (LUAD), which is the most important and common subtype of non-small cell lung cancer (NSCLC), is highly heterogeneous with a poor prognosis and poses great challenges to health worldwide. MicroRNAs (miRNAs) are regulators of gene expression with recognized roles in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Pengyuan, Liu, Zhenchuan, Huang, Haitao, Zhong, Chongjun, Zhou, Yongxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534871/ https://www.ncbi.nlm.nih.gov/pubmed/33061457 http://dx.doi.org/10.2147/OTT.S265859

Ejemplares similares

Lipids for CD8(+) TILs: Beneficial or harmful?
por: Wu, Duojiao, et al.
Publicado: (2022)

Long Noncoding RNA FAM225A Promotes Esophageal Squamous Cell Carcinoma Development and Progression via Sponging MicroRNA-197-5p and Upregulating NONO
por: Zhu, Pengyuan, et al.
Publicado: (2021)

Upregulation of glucosamine-phosphate N-acetyltransferase 1 is a promising diagnostic and predictive indicator for poor survival in patients with lung adenocarcinoma
por: Zhu, Pengyuan, et al.
Publicado: (2021)

Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression
por: Lin, Jianzhen, et al.
Publicado: (2018)

CD8+ TILS Expression in Invasive Breast Carcinoma (No Special Type)
por: Astuti, Astuti, et al.
Publicado: (2022)

Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions
por: Teng, Feifei, et al.
Publicado: (2016)

Neuroepithelial Cell Transforming Gene 1 Acts as an Oncogene and Is Mediated by miR-22 in Human Non-Small-Cell Lung Cancer
por: Ding, Shengguang, et al.
Publicado: (2020)

Biomarkers of tumor-reactive CD4(+) and CD8(+) TILs associate with improved prognosis in endometrial cancer.
por: Palomero, Jara, et al.
Publicado: (2022)

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients
por: Kvistborg, Pia, et al.
Publicado: (2012)

miR-505 suppresses prostate cancer progression by targeting NRCAM
por: Ling, Xiao-Hui, et al.
Publicado: (2019)

miR-505 suppresses prostate cancer progression by targeting NRCAM
por: Ling, Xiao-Hui, et al.
Publicado: (2020)

Association between radiomics features of DCE-MRI and CD8(+) and CD4(+) TILs in advanced gastric cancer
por: Huang, Huizhen, et al.
Publicado: (2023)

505 Verdades publicitarias /
por: Pratt Gaballí, Pedro
Publicado: (2001)

Microbiome Related Cytotoxically Active CD8+ TIL Are Inversely Associated With Lung Cancer Development
por: Zheng, Leliang, et al.
Publicado: (2020)

MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8(+) T lymphocytes in human diffuse large B cell lymphoma
por: Xu, Yangyang, et al.
Publicado: (2020)

Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer
por: Wang, Yumeng, et al.
Publicado: (2022)

Fewer tumour-specific PD-1(+)CD8(+) TILs in high-risk “Infiltrating” HPV(−) HNSCC
por: Xu, Ke, et al.
Publicado: (2020)

Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors
por: Baram, Tamir, et al.
Publicado: (2021)

miR‐505 inhibits proliferation of osteosarcoma via HMGB1
por: Li, Guangzhang, et al.
Publicado: (2020)

High post‐chemotherapy TIL and increased CD4+TIL are independent prognostic factors of surgically resected NSCLC following neoadjuvant chemotherapy
por: Jia, Wenxiao, et al.
Publicado: (2023)

CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast
por: Rathore, Ankita Singh, et al.
Publicado: (2014)

CD8+ TIL Recruitment May Revert the Association of MAGE A3 with Aggressive Features in Thyroid Tumors
por: Martins, Mariana Bonjiorno, et al.
Publicado: (2014)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Uncovering PD-L1 and CD8(+) TILS Expression and Clinical Implication in Cervical Squamous Cell Carcinoma
por: Chen, Jingjing, et al.
Publicado: (2020)

Concordance of PD-L1 expression and CD8(+) TIL intensity between NSCLC and synchronous brain metastases
por: Batur, Sebnem, et al.
Publicado: (2020)

CD8(+) TILs in NSCLC differentiate into TEMRA via a bifurcated trajectory: deciphering immunogenicity of tumor antigens
por: Lee, Sung-Woo, et al.
Publicado: (2021)

Fysikkpris til Fanamann
Publicado: (1981)

Petabytes til folket
Publicado: (2005)

Goldilocks and the three TILs
por: Dada, Hannah, et al.
Publicado: (2022)

Towards next‐generation TIL therapy: TILs enriched in neoepitope‐specific T cells
por: Arnaud, Marion, et al.
Publicado: (2023)

PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells
por: Caraban, Bogdan Marian, et al.
Publicado: (2023)

miRNA Profiling of Naïve, Effector and Memory CD8 T Cells
por: Wu, Haoquan, et al.
Publicado: (2007)

SUN-505 The Invincible Parathyroid Gland
por: Mayorga, Mabel, et al.
Publicado: (2019)

Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer
por: Zurlo, Ina Valeria, et al.
Publicado: (2021)

Immunoexpression of Tumor Infiltrating Lymphocytes(TILS) CD4 + and CD8 + in Oral Squamous Cell Carcinoma (OSCC) in Correlations with Clinicopathological Characteristics and Prognosis
por: Wahbi, Hanan Salman, et al.
Publicado: (2022)

MiR-222 in Cardiovascular Diseases: Physiology and Pathology
por: Ding, Shengguang, et al.
Publicado: (2017)

Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-gene pairs in small-cell lung cancer
por: Mao, Yun, et al.
Publicado: (2019)

Rejsen til universets indre
por: Kjaer, C
Publicado: (1998)

Blue Light Til Dawn/
por: Cassandra Wilson

Nedtelling til tidenes stjernesmell
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_djqadrspt173u6gptis897cngv